Saracatinib – 50 mg

Brand:
Cayman
CAS:
379231-04-6
Storage:
-20
UN-No:
Non-Hazardous - /

Saracatinib is a dual inhibitor of the tyrosine kinases c-Src and Abl (IC50 = 2.7 and 30 nM, respectively).{24595} It less effectively inhibits other receptor and non-receptor tyrosine kinases as well as assorted serine/threonine kinases.{24595,24597,24594} Saracatinib is orally available and blocks cell motility, migration, adhesion, invasion, proliferation, differentiation, and survival.{24595,24597,24598} Through its effects on c-Src, it reduces osteoclast bone resorption.{24597} Saracatinib also blocks denque virus RNA replication through its effect on Fyn kinase.{24596}  

 

Available on backorder

SKU: 11497 - 50 mg Category:

Description

A dual inhibitor of c-Src and Abl (IC50 = 2.7 and 30 nM, respectively); less effectively inhibits other kinases; blocks cell motility, migration, adhesion, invasion, proliferation, differentiation, and survival; reduces osteoclast bone resorption


Formal name: N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methyl-1-piperazinyl)ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-4-quinazolinamine

Synonyms:  AZD 0530

Molecular weight: 542

CAS: 379231-04-6

Purity: ≥90%

Formulation: A crystalline solid


Product Type|Biochemicals|Antivirals||Product Type|Biochemicals|Kinase Inhibitors|Abl Family & Bcr-Abl||Product Type|Biochemicals|Kinase Inhibitors|SRC Family||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Cell Migration & Metastasis||Research Area|Cancer|Cell Signaling|Abl family & Bcr-Abl Signaling||Research Area|Cancer|Cell Signaling|SRC Family Signaling||Research Area|Cell Biology|Cell Signaling||Research Area|Cell Biology|ECM & Adhesion Molecules||Research Area|Endocrinology & Metabolism|Bone Growth & Remodeling||Research Area|Immunology & Inflammation||Research Area|Infectious Disease|Viral Diseases|Dengue